ÂÜÀòÂÒÂ×

Ms. de Craecker has served as a member of the X4 Board of Directors since October 2021 following a distinguished career building multi-functional teams, formulating global commercial strategies for orphan drug and gene therapy products, and successfully launching multiple products across the globe. She also currently serves as an Independent Director of the French biopharmaceutical company GenSight. Previously, she served as General Manager Europe, Middle East, and Africa (EMEA) at AveXis Europe (now a Novartis company), building the team to market, network, and distribute Zolgensma for the treatment of Spinal Muscular Atrophy (SMA) across the region. Prior to that, Ms. de Craecker served as Senior Vice President and General Manager EMEA at Raptor Pharmaceuticals Europe, where she oversaw commercial operations, medical affairs, pharmacovigilance, legal, finance, human resources, and technology operations.